Abstract
Background
The clinical importance of papillary thyroid microcarcinoma (PTMC) remains controversial, with current guidelines suggesting that thyroid lobectomy alone is sufficient. The purpose of this study was to identify population-level treatment patterns in the USA for PTMC.
Methods
Patients with PTMC in SEER (1998–2010) were included; demographic, clinical (extent of surgery, administration of post-operative radioactive iodine [RAI]), and pathologic characteristics were examined. Outcomes of interest were 5- and 10-year overall survival (OS) and disease-specific survival (DSS).
Results
The cohort consisted of 29,512 patients. Mean age at diagnosis was 48.5 years; mean tumor size was 0.53 cm. Overall, 73.4 % of patients underwent total thyroidectomy, and RAI was administered to 31.3 %. In multivariate analysis, total thyroidectomy was more frequently performed in patients with multifocal (odds ratio [OR] 2.55), ‘regional’, or ‘distant’ PTMC (OR 2.90 and 2.59). Non-operative management was associated with male patients (OR 4.24) and those aged ≥65 years (OR 6.31). Post-operative RAI was associated with multifocal PTMC (OR 2.57). Overall, 5- and 10-year DSS was 99.6 and 99.3 %, respectively, with no difference in DSS between patients who underwent partial versus total thyroidectomy. OS of patients with PTMC who underwent any thyroid operation was similar to that of the general population of the USA.
Conclusions
An increasing number of patients are undergoing total thyroidectomy and RAI for PTMC. While there may be a subset of patients for whom more aggressive therapy is indicated, many patients with PTMC may be over-treated, with no demonstrable benefit to survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
Hay ID, Hutchinson ME, Gonzalez-Losada T et al (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144:980–987
Cramer JD, Fu P, Harth KC et al (2010) Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 148:1147–1152
Simard EP, Ward EM, Siegel R et al (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin [Epub ahead of print]. doi: 10.3322/caac.20141
Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115:3801–3807
Roti E, Rossi R, Trasforini G et al (2006) Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 91:2171–2178
Ross DS, Litofsky D, Ain KB et al (2009) Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19:1043–1048
Durante C, Attard M, Torlontano M et al (2010) Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 95:4882–4888
Yu XM, Wan Y, Sippel RS et al (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
National Comprehensive Cancer Network (2013) NCCN thyroid carcinoma version 1.2013 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
National Cancer Institute. SEER: Surveillance, Epidemiology, and End Results Program [online]. Available from URL: www.seer.cancer.gov
Fritz AG, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva
Arora N, Turbendian HK, Kato MA et al (2009) Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid 19:473–477
Malandrino P, Pellegriti G, Attard M et al (2013) Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab 98:1427–1434
Ghossein R, Ganly I, Biagini A et al (2014) Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 cases. Thyroid 24:245–253
Ogilvie JB, Patel KN, Heller KS (2010) Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well-differentiated thyroid microcarcinomas. Surgery 148:1222–1226
Cappelli C, Castellano M, Braga M et al (2007) Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol 95:555–560
Ito Y, Miyauchi A, Inoue H et al (2010) An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34:28–35
Ito Y, Miyauchi A, Kihara M et al (2014) Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24:27–34
Ross DS, Tuttle RM (2014) Observing micopapillary thyroid cancers. Thyroid 24:3–6
Kuo EJ, Goffredo P, Sosa JA et al (2013) Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid 23:1305–1311
Disclosures
The authors have no relevant disclosures.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, T.S., Goffredo, P., Sosa, J.A. et al. Papillary Thyroid Microcarcinoma: An Over-Treated Malignancy?. World J Surg 38, 2297–2303 (2014). https://doi.org/10.1007/s00268-014-2602-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-014-2602-3